- Earth Science Tech has evolved into a diversified healthcare holding company with operations spanning telemedicine, compounding pharmacies, clinical support services and healthcare fulfillment.
- In addition, the company has actively reduced its share count through a series of share repurchases documented in SEC filings and share structure records.
- Earth Science Tech repurchased 3.7 million shares over the nine months ended December 31, 2025, spending approximately $647,000.
- Management continues to emphasize shareholder value through balance-sheet management alongside acquisitions and operating growth.
- The company is scheduled to present to investors at the Planet MicroCap Las Vegas 2026 conference in June.
For many investors evaluating companies on the OTC market, share structure often receives as much attention as revenue growth or acquisition activity. Earth Science Tech (OTC: ETST), a strategic holding company spanning telemedicine, pharmacies, clinical support services, and healthcare fulfillment, has increasingly distinguished itself in share structure and financial stability through a sustained program of share repurchases, which has reduced outstanding shares while the company simultaneously expands its healthcare-focused operating platform.
The company’s most recent Form 10-Q, covering the quarter ended December 31, 2025, provides a detailed look at the pace of those repurchases (https://ibn.fm/Gm12j). According to the filing, Earth Science Tech repurchased 1,143,000 common shares during the quarter for approximately $177,659 through private transactions with shareholders. The purchases included 380,000 shares acquired on October 28, 2025, at $0.08 per share and an additional 763,000 shares purchased on December 10, 2025, at $0.193 per share.
The buyback activity extends well beyond a single quarter. For the nine months ended December 31, 2025, the company reported repurchasing 3,703,296 shares for a total cost of approximately $647,087. Those transactions included purchases of 1,050,296 shares in April 2025, 1,510,000 shares in September 2025, 380,000 shares in October 2025 and 763,000 shares in December 2025.
The significance of those repurchases becomes more apparent when compared with the company’s current share structure. Earth Science Tech reported 290.6 million shares outstanding as of June 1, 2026. The same data shows a reduction of approximately 715,000 shares during the most recent three-month period, a decline of 1.8 million shares over six months and a decrease of approximately 3.69 million shares over the last twelve months. Those figures closely mirror the repurchase activity disclosed in SEC filings (https://ibn.fm/cxJkG).
The historical share structure data also provides a timeline of share reductions. Outstanding shares declined from more than 294.3 million in September 2025 to approximately 290.6 million by June 2026, reflecting a series of cancellations and repurchases over that period.
For investors accustomed to seeing microcap companies expand share counts through repeated equity issuance, Earth Science Tech’s approach stands out. The company maintains 300 million authorized shares, leaving relatively limited separation between authorized and outstanding stock. As of June 2026, approximately 215.1 million shares were classified as restricted, while the public float stood at roughly 40.8 million shares.
While share repurchases alone do not determine investment performance, they can provide insight into management’s capital allocation priorities. In ETST’s case, the reduction in outstanding shares suggests an emphasis on preserving shareholder ownership percentages while executing a broader corporate growth strategy.
The company’s growth strategy has successfully evolved over the past several years, transitioning away from its legacy wellness operations and repositioning itself as a diversified holding company focused primarily on healthcare-related businesses. The company now operates through subsidiaries involved in pharmaceutical compounding, telemedicine, clinical support services, healthcare fulfillment, real estate investments and cash management activities.
The central theme behind the model is vertical integration. Management has assembled businesses that participate in multiple stages of the patient-care process, from initial consultation and telehealth interactions to prescription fulfillment and ongoing support services. Telemedicine platforms serve as a front-end entry point for patients seeking medical consultations and treatment options. Compounding pharmacies then provide customized prescription fulfillment, creating recurring interactions that can extend over long periods.
By integrating these functions internally, the company seeks to capture value across multiple stages of the healthcare continuum rather than relying on a single revenue stream. The structure offers exposure to sectors that continue to benefit from long-term healthcare demand trends, including personalized medicine, telehealth adoption and outpatient care delivery.
At the same time, management has continued emphasizing financial discipline. The share repurchase program demonstrates a willingness to deploy capital toward reducing share count while pursuing operating expansion. That balance between acquisition-driven growth and shareholder-focused capital management has become a recurring theme in company communications.
Regarding investor visibility, the company announced that Chairman and Chief Executive Officer Giorgio R. Saumat will present at the Planet MicroCap Las Vegas 2026 Investor Conference on June 17 at the Bellagio Resort & Hotel. The event, organized in conjunction with MicroCapClub, brings together microcap companies and investors for presentations and one-on-one meetings. The conference appearance offers management an opportunity to discuss the company’s operating strategy, healthcare platform and capital allocation priorities directly with investors.
For shareholders, however, one of the clearest signals may already be visible in the numbers. While many small-cap and OTC companies face scrutiny over expanding share counts, Earth Science Tech’s recent filings and share structure records show a different pattern. More than 3.7 million shares were repurchased during the nine months ended December 2025, and the company’s outstanding share count has continued trending lower into 2026.
For more information, visit the company’s website at www.EarthScienceTech.com.
NOTE TO INVESTORS: The latest news and updates relating to ETST are available in the company’s newsroom at https://ibn.fm/ETST
